Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CFTR | P13569 | 2/20 | 0.44 |
| ▸ | CSF1R | P07333 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15129379 | 0.89 | KDM4E (0.48) | KDM4EHSD17B10ALDH1A1CFTRCSF1R | |
| SCHEMBL5989774 | 0.89 | CYP2C9 (0.47) | KDM4EHSD17B10ALDH1A1CFTRCSF1R | |
| SCHEMBL1077964 | 0.88 | PTGS2 (0.45) | KDM4EHSD17B10ALDH1A1CFTRCSF1R | |
| SCHEMBL15129458 | 0.86 | KDM4E (0.44) | KDM4EHSD17B10ALDH1A1CFTRCSF1R | |
| SCHEMBL4545983 | 0.84 | MAPT (0.49) | KDM4EHSD17B10ALDH1A1CFTRMAPT | |
| SCHEMBL1076287 | 0.83 | KMT2A (0.46) | KDM4EALDH1A1CSF1RMAPTNPC1 | |
| SCHEMBL19367435 | 0.81 | KDM4E (0.47) | KDM4EHSD17B10ALDH1A1CSF1RMAPT | |
| SCHEMBL1342821 | 0.81 | KDM4E (0.47) | KDM4EHSD17B10ALDH1A1CSF1RMAPT | |
| SCHEMBL1341502 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1CSF1RMAPTHPGD | |
| SCHEMBL15129494 | 0.80 | L3MBTL1 (0.42) | KDM4EALDH1A1CSF1RMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074882-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 5-[(4-BROMO-2-FLUOROPHENYL)AMINO]-4-FLUORO-N-(2HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2025-03-06 | — | — | US | disclosed |
| WO-2023131976-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 5-[(4-BROMO-2-FLUOROPHENYL)AMINO]-4-FLUORO-N-(2HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-07-13 | — | — | WO | disclosed |
| WO-2020212832-A1 | PROCESS OF PREPARATION OF BENZIMIDAZOLE COMPOUNDS | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020212832-A1 | PROCESS OF PREPARATION OF BENZIMIDAZOLE COMPOUNDS | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074882-A1 | IMPROVED PROCESS FOR THE PREPARATION OF 5-[(4-BROMO-2-FLUOROPHENYL)AMINO]-4-FLUORO-N-(2HYDROXYETHOXY)-1-METHYL-1H-BENZIMIDAZOLE-6-CARBOXAMIDE | ABL1, JAK1, FGFR1 | KDM4E 51/4885HSD17B10 2406/4885ALDH1A1 1448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.